Independent directory Public ClinicalTrials.gov records United States
Location Directory

Clinical trials in Seattle, Washington

This page shows live ClinicalTrials.gov search results for Seattle, Washington, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 3:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
11423
Shown on this page
12
Current sort
Recently updated
Location scope
Seattle, WA
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Seattle, Washington. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 949–960 of 11,423 matching trials in Seattle, WA.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Seattle

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Conditions
Type B Aortic Dissection
Interventions
TEVAR, Guideline directed medical therapy and surveillance of dissection
Procedure · Other
Lead sponsor
Duke University
Other
Eligibility
21 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
64
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 54 more
Active, not recruiting Phase 2 Interventional Results available

Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease

NCT04198922
Conditions
Recurrent Moderate-Severe Chronic Graft Versus Host Disease, Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Acalabrutinib, Questionnaire Administration
Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
6
States / cities
Tampa, Florida • Buffalo, New York • Columbus, Ohio + 3 more
Conditions
Psoriatic Arthritis
Interventions
Zasocitinib, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
22
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 19 more
Conditions
Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
ponsegromab, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
982 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
91
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 48 more
Conditions
Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Colorectal Neoplasms
Interventions
E7386, Lenvatinib, Doxorubicin, Paclitaxel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
28
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 22 more
Conditions
Secondary Immune Deficiency
Interventions
IgPro20
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
17
States / cities
Orange, California • Denver, Colorado • Coral Springs, Florida + 14 more
Conditions
Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization, Healthy Volunteers
Interventions
RSV+HMPV vaccine, Control Vaccine 3, Control Vaccine 4, Control Vaccine 2, Placebo, Control Vaccine 1
Biological · Other
Lead sponsor
Sanofi
Industry
Eligibility
60 Years and older
Enrollment
2,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
50
States / cities
Gadsden, Alabama • Vestavia Hills, Alabama • Huntington Beach, California + 43 more
Conditions
Acute HIV Infection
Interventions
VRC07-523LS, PGT121.414.LS, Placebo, ART
Biological · Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
9
States / cities
Birmingham, Alabama • Aurora, Colorado • Atlanta, Georgia + 6 more
Conditions
Major Depressive Disorder (MDD)
Interventions
DT-101, Placebo
Drug
Lead sponsor
Draig Therapeutics Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
23
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 17 more
Conditions
Female Contraception
Interventions
Transdermal system containing progestin
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
16 Years and older · Female only
Enrollment
1,630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
56
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 40 more
Conditions
Breast Cancer, Early Breast Cancer
Interventions
Camizestrant, Tamoxifen, Anastrozole, Letrozole, Exemestane
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
4,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
126
States / cities
Birmingham, Alabama • Dothan, Alabama • Anchorage, Alaska + 110 more
Conditions
Prostate Cancer
Interventions
enzalutamide, abiraterone acetate, prednisone, Leuprolide acetate
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
46
States / cities
Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 38 more